Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Brigham and Women's Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07417618CT.gov INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | — | Active Not Recruiting | — | — | — |
NCT07096063CT.gov Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | — | Completed | — | — | — |
NCT05900531CT.gov A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers | — | Completed | — | — | — |
NCT03101930CT.gov Cardiovascular Effects of GLP-1 Receptor Activation | — | Completed | — | — | — |
NCT02697253CT.gov Mechanisms Underlying Predictors of Success From Obesity Surgery | — | Withdrawn | — | — | — |
NCT02527993CT.gov Treatment of Hypoglycemia Following Gastric Bypass Surgery | — | Completed | — | — | — |
NCT01701973CT.gov Effect of DPP4 Inhibition on Growth Hormone Secretion | — | Completed | — | — | — |
NCT01073826CT.gov Role of Interleukin-6 in Exercise | — | Completed | — | — | — |
NCT00842400CT.gov A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects. | — | Completed | — | — | — |
NCT00795275CT.gov Incretin Effect in People With Impaired Fasting Glucose | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sitagliptin (this asset) | Brigham and Women's Hospital | Approved | BB · 66 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Sitagliptin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P4 | BBB · 73 |
| Polycystic Ovary Syndrome | — | P4 | BB · 70 |
| Prediabetes Syndrome | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sitagliptin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sitagliptin-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →